RNA Therapy Improves Vision in Child Blindness; Hear More About Recent Developments in RNA Therapy at RNA Therapeutics 2019
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
London, United Kingdom, January 04, 2019 --(PR.com)-- Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved the vision of LCA-affected children in a small clinical study.*
The field of RNA therapeutics has seen dramatic, positive developments in the last few years, moving towards the path of treatment for multiple conditions where the current standard of therapy is failing.
The study, published in Nature Medicine, found one patient improve from only being able to differentiate light or dark, to reading letters on an eye chart two months after the first injection.
Antisense oligonucleotides, used in the above study, were found to influence RNA processing and modulate protein expression over 20 years ago and much progress has been made translating these agents into a clinical setting.
This year’s RNA Therapeutics Conference, returning to London, UK on 20th – 21st February for its 10th year running, is set to deliver in-depth presentations from senior, internationally renowned industry experts including Exicure, Roche, MHRA, Dicerna Pharmaceuticals, Accanis Biotech, Ethris, Alnylam, and many more.
Focused presentations on oligonucleotide therapies, opportunities and challenges in drug developments, and securing oligonucleotide supply include:
“Advances in Targeted Delivery of Anti-Sense Oligonucleotide Therapeutics to Pancreatic SS-Cells for Regenerative Approaches in Type 2 Diabetes,” presented by Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca.
“Delivering Therapeutic Oligonucleotides across Biobarriers: Opportunities and Challenges in Drug Development,” presented by Ekkehard Leberer, Senior Director, Sanofi-Aventis Deutschland GmbH.
“Planning for Oligonucleotide Supply: Personalized Medicine to Large Scale Markets,” presented by Hans Kistemaker, Associate Director, ProQR.
Visit the website for more information and to download the latest brochure with the full agenda and speaker line-up, as well as other exclusive content at: http://www.therapeutics-rna.com/prcom
10th Annual RNA Therapeutics Conference
20th – 21st February 2019
London, UK
*Nature.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The field of RNA therapeutics has seen dramatic, positive developments in the last few years, moving towards the path of treatment for multiple conditions where the current standard of therapy is failing.
The study, published in Nature Medicine, found one patient improve from only being able to differentiate light or dark, to reading letters on an eye chart two months after the first injection.
Antisense oligonucleotides, used in the above study, were found to influence RNA processing and modulate protein expression over 20 years ago and much progress has been made translating these agents into a clinical setting.
This year’s RNA Therapeutics Conference, returning to London, UK on 20th – 21st February for its 10th year running, is set to deliver in-depth presentations from senior, internationally renowned industry experts including Exicure, Roche, MHRA, Dicerna Pharmaceuticals, Accanis Biotech, Ethris, Alnylam, and many more.
Focused presentations on oligonucleotide therapies, opportunities and challenges in drug developments, and securing oligonucleotide supply include:
“Advances in Targeted Delivery of Anti-Sense Oligonucleotide Therapeutics to Pancreatic SS-Cells for Regenerative Approaches in Type 2 Diabetes,” presented by Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca.
“Delivering Therapeutic Oligonucleotides across Biobarriers: Opportunities and Challenges in Drug Development,” presented by Ekkehard Leberer, Senior Director, Sanofi-Aventis Deutschland GmbH.
“Planning for Oligonucleotide Supply: Personalized Medicine to Large Scale Markets,” presented by Hans Kistemaker, Associate Director, ProQR.
Visit the website for more information and to download the latest brochure with the full agenda and speaker line-up, as well as other exclusive content at: http://www.therapeutics-rna.com/prcom
10th Annual RNA Therapeutics Conference
20th – 21st February 2019
London, UK
*Nature.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Maria Mandic
+44 020 7827 6000
http://www.therapeutics-rna.com/prcom
Maria Mandic
+44 020 7827 6000
http://www.therapeutics-rna.com/prcom
Contact
Categories